Mapping the sorry landscape across 11 CNS diseases reveals something that individual disease pages cannot:
the shape of the unknown. Six diseases have no diagnostic biomarker. Five have no disease-modifying treatment. Six have unknown mechanisms. These aren't separate problems — they're the same problem wearing different disease codes.
The pattern is consistent:
target engagement ≠ clinical benefit (Tominersen),
diagnosis without biology (depression, schizophrenia, ADHD), and
structural barriers that immunotherapy cannot penetrate (ALS microenvironment, PDAC stroma). The bonixer forces you to state what you know, what you don't, and what that gap costs.
Pancreas is next. The sechive bonixer is now being applied to pancreatic disease — testing whether it has a "real proper one" (like teplizumab for T1D prevention) or is deep in sorry territory (like PDAC's 40-year KRAS wall). The sorry methodology scales. The attack surface is now visible.
→ Open Pancreatic Disease Bonixer · PANC-001